Lipid-Based Drug Delivery Systems in Myocardial Fibrosis Treatment

Myocardial fibrosis (MF) involves the abnormal buildup of extracellular matrix (ECM) components, primarily collagen and fibronectin, in cardiac tissue. This condition is commonly associated with various cardiovascular diseases and is a major contributor to cardiac dysfunction and heart failure. At Creative Biolabs, we utilize our advanced lipid-based drug delivery systems to synergize with innovative therapeutic strategies, facilitating precise targeting and effective treatment of MF.

Background of MF Treatment

Cardiomyocytes (CMs), the predominant cell population in the heart, are integral to the development of MF.
Under pathological conditions such as heart failure, injury stimuli—including mechanical stress, metabolic dysfunction, and inflammation—activate pro-fibrotic programs in CMs. This activation promotes the proliferation of cardiac fibroblasts (CFs) and their differentiation into cardiac myofibroblasts (CMFs), which are the primary sources of ECM overproduction in MF. Notably, activated CFs are not confined to the heart, they also contribute to fibrosis and adverse remodeling in various tissues, including the liver, lungs, and tumors.

Fig.1 Interactions between different cardiac cells involved in the development of cardiac fibrosis.¹

Treatment Strategies for MF

• Pharmacotherapy

The differentiation of CFs into CMFs is central to the progression of MF. Creative Biolabs provides a range of pharmacological interventions, such as ACE inhibitors, ARBs, and thiazolidinediones (TZDs), which effectively impede the progression of MF by targeting fibrosis-related signaling pathways. Additionally, we provide liposome preparation services for small molecules, proteins/peptides, prodrugs, and nucleic acids, ensuring efficient drug delivery and precise targeting.

• Macrophage Depletion

When cardiac tissue is damaged, macrophages stimulate CF proliferation by secreting cytokines and growth factors or directly transform into CF/CMFs, promoting ECM deposition. Creative Biolabs offers a wide range of clodronate liposome products that selectively deplete pro-fibrotic macrophages, effectively reducing fibrosis. This strategy not only improves the pathological state of myocardial fibrosis but also offers new possibilities for cardiac function recovery.

• Chimeric Antigen Receptor (CAR) T-Cell Therapy

CAR-T cell therapy involves genetically engineering T cells (via viral transfection, electroporation, LNP, etc.) to express specific antigen-binding domains, enabling them to directly bind to and activate against tumor-specific antigens, releasing perforin and granzyme B to kill tumor cells. Utilizing our cutting-edge LNP platform, Creative Biolabs can encapsulate and deliver the necessary genetic material for CAR-T cell engineering, thereby effectively inhibiting and potentially reversing myocardial fibrosis.

• mRNA Vaccine Therapy

The core of mRNA vaccine therapy lies in using mRNA to encode specific antigens or functional proteins, activating the immune system to treat MF. Lipid-based drug delivery systems are crucial carriers for mRNA vaccines. At Creative Biolabs, we are pioneering the integration of mRNA therapy with our state-of-the-art lipid-based delivery systems to create a powerful therapeutic platform for myocardial fibrosis. Learn more about our liposome-based adjuvant development service.

• Biomimetic Therapy

Biomimetic therapy commonly utilizes cells, cell membranes (e.g., leukocytes, erythrocytes, platelets, stem cells), lipoproteins, and exosomes, with cell membrane- and exosome-based therapies being the most prevalent. By integrating biomimetic materials with lipid-based drug delivery systems, Creative Biolabs creates nanoparticles encapsulated within cell membranes. These nanoparticles can mimic endogenous substances, evading immune system recognition, thereby minimizing toxicity and enhancing therapeutic efficacy.

Creative Biolabs is committed to providing comprehensive treatment solutions for myocardial fibrosis by integrating advanced lipid-based drug technologies with innovative strategies such as biomimetic therapy, CAR-T cell therapy, macrophage depletion, and mRNA vaccines. If you are interested in exploring how our lipid-based drug delivery systems can enhance your therapeutic strategies for myocardial fibrosis, we invite you to contact us.

For Research Use Only. Not For Clinical Use